Article
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
International journal of cancer - 15 Jun 2017
Yang Zuyao, Hackshaw Allan, Feng Qi, Fu Xiaohong, Zhang Yuelun, Mao Chen, Tang Jinling
Abstract excerpt
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non-small cell lung cancer (NSCLC) with proven efficacy. We undertook a systematic review and meta-analysis to synthesize existing studies with dir...
Topics
- Afatinib
- Carcinoma, Non-Small-Cell Lung
- Diarrhea
- Disease-Free Survival
- ErbB Receptors
- Erlotinib Hydrochloride
- Exanthema
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Outcome Assessment, Health Care
- Proportional Hazards Models
- Protein Kinase Inhibitors
- Quinazolines
- Randomized Controlled Trials as Topic